Chiasma, a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital. The round also included investments from existing shareholders. The proceeds will be used complete the phase 3 trial of Octreolin, the company’s proprietary oral form of the peptide octreotide, which is planned to be completed in the second quarter of 2013. Chiasma, based in Jerusalem, is developing oral drugs that previously were only available by injection, thereby providing patients with pain-free medications that are self-administered.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

People With Autism Experience Higher Intensity Pain
January 30, 2023

Israeli Innovation At New Bahraini Hospital
January 30, 2023

US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023

Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments